Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of WCK 5222 on QT/QTc Interval in Healthy Volunteers
NCT03554304Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cefepime + zidebactam in bacterial infection (3 arms), sponsored by Wockhardt. Primary endpoint: Incidence of delay in cardiac repolarization induced by WCK 5222. Started Feb 2017; status: completed.
02
Drugs
cefepime + zidebactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03554304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554304.